# Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

> **NCT05346809** · PHASE2 · RECRUITING · sponsor: **Divaya Bhutani** · enrollment: 39 (estimated)

## Conditions studied

- Lymphoma
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Relapsed Hodgkin's Disease, Adult

## Interventions

- **DRUG:** Isatuximab
- **OTHER:** Standard Procedures

## Key facts

- **NCT ID:** NCT05346809
- **Lead sponsor:** Divaya Bhutani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-31
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05346809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05346809, "Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05346809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*